Archives

Transforming RSV Prevention: The Role and Challenges of Nirsevimab

This entry is part 2 of 16 in the series Mar 2024

Nirsevimab (Beyfortus) is a significant advancement in the prevention of Respiratory Syncytial Virus (RSV) in infants, providing lasting protection with one dose, but its equitable distribution faces logistical, financial, and systemic hurdles, and necessitates tailored approaches in vulnerable communities like the American Indian or Alaska Native population.

Read more
Recent Entries »